CN111973633A - Application of endothelial progenitor cells in preparation of medicine for preventing or treating acute altitude disease - Google Patents
Application of endothelial progenitor cells in preparation of medicine for preventing or treating acute altitude disease Download PDFInfo
- Publication number
- CN111973633A CN111973633A CN202010939222.5A CN202010939222A CN111973633A CN 111973633 A CN111973633 A CN 111973633A CN 202010939222 A CN202010939222 A CN 202010939222A CN 111973633 A CN111973633 A CN 111973633A
- Authority
- CN
- China
- Prior art keywords
- progenitor cells
- endothelial progenitor
- medicament
- preparation
- altitude
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/44—Vessels; Vascular smooth muscle cells; Endothelial cells; Endothelial progenitor cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Cell Biology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Developmental Biology & Embryology (AREA)
- Engineering & Computer Science (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Zoology (AREA)
- Virology (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
Abstract
The invention provides an application of endothelial progenitor cells in preparation of a medicament for preventing or treating acute altitude sickness, wherein the acute altitude sickness is generated in a plateau environment with an altitude of more than 2000 m. The invention also discloses a protective effect of the endothelial progenitor cells on pulmonary edema, cerebral edema and the like of a mouse simulating 5500m plateau environment.
Description
Technical Field
The invention belongs to the field of biological medicines, and particularly relates to application of endothelial progenitor cells in a medicine for preventing or treating acute altitude sickness.
Background of the study
A altitude disease is a natural physiological reaction generated by a human body to adapt to changes of air pressure difference, low oxygen content, air dryness and the like caused by altitude after the human body reaches a certain altitude. Symptoms of altitude sickness are generally manifested as headache, palpitation, tiredness, chest distress, shortness of breath, vomiting, anorexia, convulsions, absentmindedness, and sudden decline in cognitive ability. The physical signs include accelerated heart rate, deepened respiration, slight abnormal blood pressure, edema of face or limbs, cyanosis of lips, etc. The altitude diseases are classified into acute altitude diseases and chronic altitude diseases.
The acute altitude disease comprises altitude coma, altitude cerebral edema, altitude pulmonary edema, altitude retinal hemorrhage or mixed diseases with the simultaneous existence of abnormal symptoms of the cerebral and pulmonary diseases.
At present, the main common medicines for preventing and treating altitude diseases are acetazolamide which can rapidly improve the body adaptability, but the improvement of the habitual taking and the anoxia adaptability is always limited, the anoxia environment in vivo is not improved, the damage to the nervous system is more and more serious along with the prolonging of time, and various neurophysiological and psychological clinical symptoms are shown.
Patent document CN 103829245 a discloses a food for regulating altitude sickness and a preparation method thereof, wherein the food is prepared by rolling, molding and baking wheat, wheat fiber, radix puerariae, semen cassiae, fructus cannabis, ginseng, poria cocos, houttuynia cordata, honeysuckle, fructus lycii, bunge cherry seed, Chinese yam, chrysanthemum, oyster, sea buckthorn, lotus seed, malt, dried ginger, liquorice, spina date seed, peach seed, almond, mulberry leaf, papaya, lily, dried orange peel and dried ginger into raw material powder, water, glucose, isomaltooligosaccharide, food additives soybean concentrated phospholipid and a leavening agent in a certain weight ratio, wherein the raw material powder is prepared into dough.
Patent document CN 103948896 a discloses an anti-altitude disease composition and its application, the composition contains a traditional Chinese medicine extract, and the traditional Chinese medicine extract is prepared from the following traditional Chinese medicine raw materials in parts by weight: 50-80 parts of longan seeds, 40-52 parts of Chinese waxgourd peels, 15-25 parts of pseudo-ginseng and 15-25 parts of dried ginger. The composition can effectively relieve symptoms of headache, anorexia, listlessness, debilitation, dizziness, etc. caused by altitude sickness, and provides a new choice for clinical prevention and treatment of altitude stress and relief of various symptoms caused by altitude stress.
Patent document CN 104274808A discloses a traditional Chinese medicine composition with anti-altitude disease, which comprises 10-38 parts of Tibetan lilac daphne root, 10-40 parts of rhodiola crenulata, 5-10 parts of Tibetan sea buckthorn, 8-28 parts of longan seed, 12-26 parts of Chinese waxgourd peel, 5-15 parts of pseudo-ginseng and 5-13 parts of dried ginger.
Patent document CN 104288262 a discloses a method for preparing a high altitude stress resistant drug, comprising the steps of: (1) preparing thick paste of rhodiola crenulata and Tibet daphne genkwa root; (2) preparing malus toringoides dry powder; (3) and (3) mixing the raw materials.
Patent document CN 104288735 a discloses a traditional Chinese medicine for treating altitude diseases, which comprises radix astragali, radix Panacis Quinquefolii, radix Acanthopanacis Senticosi, radix Rhodiolae, polydatin, semen Ziziphi Spinosae, rhizoma Polygonati, radix Ophiopogonis, longan seed, rhizoma Zingiberis, exocarpium Benincase, magnesium stearate and flos Carthami in parts by weight, slicing, parching and pulverizing the raw materials respectively, decocting in a decocting pot, mixing the decoctions, and filtering to obtain a medicinal liquid.
Patent document CN 108434439 a discloses an application of calreticulin in preparing a medicament for preventing and/or treating acute altitude sickness. The calreticulin can relieve pulmonary edema and cerebral edema of a mouse model simulating the altitude anoxia, improve the acid-base balance disorder caused by tissue anoxia and anoxia, and has a treatment effect similar to that of dexamethasone.
The prior art discloses the application of medicines or related health-care products such as rhodiola rosea, Gaoyuanning, American ginseng, salvia miltiorrhiza pills, Baifuning, calreticulin and the like in preventing or treating acute altitude diseases, but the medicines or the foods have the defects of slow effect, more side effects and the like.
Endothelial Progenitor Cells (EPCs) are a group of precursor cells with high proliferative potential that can differentiate into vascular endothelium, are anti-inflammatory and antioxidant, can replace apoptotic or necrotic endothelial cells, and participate in post-injury angiogenesis.
Zhang Jingchen et al, in "research progress on protection of endothelial progenitor cells against acute lung injury" (J.Zhonghua cell & Stem cell, Vol.4, No. 3 of 8 months 2014) disclose the use of endothelial progenitor cells in the treatment of acute lung injury.
Patent CN 108273041 a discloses a preparation made of endothelial progenitor cells, vascular endothelial factor, umbilical cord stem cell conditioned medium and matrigel, which can promote the healing of skin wound.
Anlii et al, in the study on the prevention and treatment effects of monocrotaline-induced hepatic vein occlusion by endothelial progenitor cells (J.E. Experimental hematology, China 2020; 28 (1); 242-.
So far, no report on the application of endothelial progenitor cells to acute altitude diseases is available.
Disclosure of Invention
The invention aims to provide application of endothelial progenitor cells in preparing a product for preventing or treating acute altitude sickness.
The invention provides application of endothelial progenitor cells in preparation of a medicament for preventing or treating acute altitude diseases.
The Endothelial Progenitor Cells (EPCs) are a group of precursor cells with high proliferation potential which can be differentiated towards vascular endothelium, have anti-inflammatory and anti-oxidation properties, can replace apoptotic or necrotic endothelial cells, and participate in angiogenesis after injury.
The endothelial progenitor cells are obtained from animal peripheral blood, bone marrow and cord blood; the endothelial progenitor cells contain CD31, CD33, CD133 and VEGF surface antigen; the endothelial progenitor cells are labeled with the dye PKH 26.
In one embodiment of the invention, the application of the endothelial progenitor cells in preparing a medicament for preventing or treating acute altitude sickness is provided.
The acute altitude disease is selected from acute altitude diseases generated in altitude environment.
Preferably, the plateau environment is above the altitude of 2000m and has low pressure and anoxic conditions.
Further preferably, the plateau environment is above an altitude of 2700m and has low pressure and oxygen deficiency.
In one embodiment of the present invention, the plateau environment is above 5500m in altitude, and has low pressure and oxygen-deficient conditions.
The acute altitude disease comprises altitude coma, altitude cerebral edema, altitude pulmonary edema, altitude retinal hemorrhage or mixed diseases with cerebral pulmonary abnormality.
Furthermore, the endothelial progenitor cells can be used for preparing a medicament for preventing or treating acute altitude diseases, and the preparation form of the medicament can be injection.
Furthermore, the medicine contains endothelial progenitor cells and pharmaceutically acceptable auxiliary materials, and can be used for preventing or treating acute altitude diseases.
The pharmaceutically acceptable auxiliary materials are selected from one or the combination of more than two of pH regulator, surfactant, suspending agent, antioxidant, isotonic regulator, bacteriostatic agent, filler and protein drug protective agent.
The storage temperature of the drug is 30-40 ℃, preferably, the storage temperature of the drug is 37 ℃.
The preparation form of the medicament can be injection.
The pharmaceutical preparation is preferably in unit dosage form. In this form, the preparation is subdivided into unit doses containing appropriate quantities of the active component. The unit dosage form can be a packaged preparation, the package containing discrete quantities of the preparation.
The content of endothelial progenitor cells in the unit preparation of the medicine can be 1 × 105One/ml to 10X 105The ratio of the active ingredient to the total amount of active ingredient is varied or adjusted depending on the particular application and the potency of the active ingredient. The medicament may also contain other suitable therapeutic agents if desired.
Preferably, the content of endothelial progenitor cells per unit preparation of the medicament may be 1X 105 2X 10 pieces/ml53X 10 pieces/ml54X 10 pieces/ml55X 10 pieces/ml56X 10 pieces/ml57X 10 pieces/ml58 × 10 pieces/ml5Each/ml, 9X 105Each/ml, 10X 105One per ml.
Pharmaceutically acceptable carriers will depend in part on the drug being administered and on the particular method of administration of the drug. Thus, there are various suitable formulations of the medicament of the present invention.
In the context of the present invention, the dosage administered to a subject should be sufficient to produce a beneficial therapeutic response in the subject over time. The dosage will depend upon the potency of the particular compound employed and the condition of the subject, as well as the body weight or body surface area of the subject to be treated. The size of the dose will depend upon the presence, nature and extent of any adverse side effects that accompany the administration of the particular compound in a particular subject. In determining an effective amount of a compound to be administered in the treatment or prevention of the condition being treated, a physician can assess factors such as the circulating plasma levels of the compound, the toxicity of the compound, and/or the course of the disease.
In one embodiment of the invention, the EPCs have a protective effect on cerebral edema, pulmonary edema and the like of a mouse simulating 5500m acute plateau environment, and can be developed into a product for preventing or treating acute altitude diseases.
Drawings
The accompanying drawings, which are incorporated in and constitute a part of this application, illustrate embodiments of the application and, together with the description, serve to explain the application and are not intended to limit the application.
FIG. 1: changes of lung dry-wet weight ratio, brain dry-wet ratio and RV/HW of each group of mice;
FIG. 2: changes in IL-6 and TNF- α in the heart, brain and lungs of each group of mice;
FIG. 3: changes in RBC, HGB and HCT in each group of mice.
Detailed Description
It should be noted that the following detailed description is exemplary and is intended to provide further explanation of the disclosure. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this application belongs.
Example 1 preparation of endothelial progenitor cells
Endothelial progenitor cells were taken from the femur and tibia of four-week-old Sprague-Dawley male rats. The SD male rat is killed by removing the neck, the killed rat is placed in 75% alcohol to be soaked for 5 minutes, and then the rat is moved into a super clean bench; using a straight-pointed surgical scissors to take out the femur and the tibia of the rat, and using an eye surgical scissors to remove connective tissues; soaking all bones in a glass dish containing 75% alcohol for 3 minutes, clamping the bones into the glass dish containing PBS solution one by using sterile ophthalmic forceps, repeatedly washing for 3 times, and finally placing the washed bones in an M199 culture medium; the rongeur cuts off two ends of a bone, the syringe is used for sucking the M199 culture medium to repeatedly wash the marrow cavity, and the marrow cavity is washed until the marrow cavity is whitish; filtering the bone marrow flushing fluid by a 200-mesh filter screen, collecting the filtered bone marrow flushing fluid into a 50ml centrifuge tube, placing the centrifuge tube in a centrifuge for centrifugation (1000rpm, 18 ℃, 5min), and preparing Percoll density gradient centrifugate (3ml Percoll stock solution +2.6ml 1 XPBS solution +0.4ml 10 XPBS solution) in the centrifugation process; removing supernatant, adding 6ml of M199 culture medium, blowing uniformly, slowly dripping into a centrifuge tube filled with 6ml of Percoll solution along the tube wall, and centrifuging in a centrifuge (2500rpm, 18 ℃, 20 min); sucking the middle white membranous substance by a disposable 10ml plastic suction tube, placing the middle white membranous substance in another 15ml centrifuge tube, adding 5ml M199 culture medium into the centrifuge tube, gently blowing uniformly, and then centrifuging (1000rpm, 18 ℃, 5 min); removing supernatant, adding 5ml M199 culture medium, blowing gently, and centrifuging (1000rpm, 18 deg.C, 5 min); preparing an endothelial progenitor cell culture medium (50% ECM, 40% M199, 10% FBS) in the centrifugation process, removing a supernatant after centrifugation, adding the endothelial progenitor cell culture medium, slowly blowing uniformly, placing in a 10cm culture dish, labeling, and transferring into a cell culture box for primary culture. The medium was changed after 48 hours, after which the cell culture medium was changed every 3 days.
Example 2 materials and methods
2.1 animals
72 mice (about 25g, male, clean grade) C57, purchased from beijing weitonglihua laboratory animals ltd, license number: SCXK (Kyoto) 2016-. Feeding in low pressure oxygen chamber, feeding with complete nutrition feed at room temperature of 22-25 deg.C and humidity of 30% -50%.
2.2 reagents and samples
Endothelial progenitor cells were obtained autonomously from the laboratory and taken from rat bone marrow. Endothelial cell culture medium for cell culture was purchased from ScienCell, usa, and bovine serum albumin was purchased from beverydi biotechnology, beijing.
2.3 instruments
A small animal low pressure oxygen cabin (tobacco platform ice wheel hyperbaric oxygen cabin ltd); oven (Shanghai Bo Xun 9140MBE (101-2 BS); five-classification blood analyzer (China broadcast and television MERK-7300P)
2.4 Experimental design and procedure
The 72 mice were randomly divided into 6 groups, 3d control group, 3d model group, 3dEPCs group, 7d control group, 7d model group, 7dEPCs group, 12 per group. Wherein 4 groups of the model group and the EPCs are arranged in an experiment chamber, the pressure in the chamber is adjusted to 380mmHg, the plateau environment with an altitude of 5500 meters is simulated, and the environment where the mouse is located is kept at 12: alternating day and night for 12 hours. The EPCs group before entering the capsule are respectively injected into 5 multiplied by 10 by the tail vein5One/only endothelial progenitor cells, model group was injected via tail vein into cell culture medium. Mice were sacrificed after 3d and 7d, respectively, and the material was taken. The control mice were housed in the same room under atmospheric and normoxic conditions.
2.5 index detection method
(1) Measuring the dry-wet weight ratio of the lung, the dry-wet weight ratio of the brain and the right heart index of each group of animals, after the animals die in an anesthesia place, dissecting the chest cavity, taking out the lung lobes on both sides under aseptic condition, carefully removing extrapulmonary tissues, rinsing with physiological saline solution at 4 ℃, after the lung lobes on the left side are dried by suction through filter paper, separating the lung lobes on the left side, weighing the lung wet mass by an electronic balance, placing the lung leaves in a constant-temperature drying box at 80 ℃ for drying for 48h until the lung wet mass is constant, weighing the lung dry mass, and calculating the lung dry-wet ratio (lung dry mass/lung wet mass. Rapidly stripping the whole brain, sucking off blood on the surface by using filter paper, placing the left lateral brain tissue in a weighing bottle, precisely weighing, drying in a constant-temperature drying oven at 80 ℃ for 48h until the mass is constant, weighing the brain stem mass, and calculating the brain stem-to-wet ratio (dry lung mass/wet lung mass, D/W). And (5) putting the rest of the right lung lobe and brain tissues into liquid nitrogen for freezing and storing for later use. After the heart tissue is taken out, the atrial tissue and the attached fat are removed, the left ventricle and the right ventricle are separated, the filter paper absorbs the water, the weights are respectively calculated, and the right heart index (right heart/whole heart, RV/HW) is calculated.
(2) Thawing heart, brain and lung tissues with TNF-alpha and IL-6 content in heart, brain and lung tissues in liquid nitrogen at room temperature in ice bath, weighing appropriate amount of tissues, homogenizing with sterile PBS solution as homogenizing medium in ice bath at a ratio of 1g/10mL to obtain 10% homogenate, centrifuging at low temperature for 3500r.min-1Centrifuging for 15min, collecting supernatant, diluting with sterile PBS solution to obtain 1% tissue homogenate, measuring protein content, and measuring TNF-alpha and IL-6 content respectively. Protein quantification is carried out by BCA method, and TNF-alpha and IL-6 are measured by ELISA method.
(3) RBC, HGB and HCT measurement in Whole blood 0.5ml of whole blood was placed in an EDTA-containing anticoagulation tube and Red Blood Cells (RBC), Hemoglobin (HGB) and Hematocrit (HCT) were measured using a fully automatic five-class cytometer.
2.6 statistical methods
All data are expressed by x +/-s, the comparison among groups is carried out by one-factor variance analysis, the difference is shown as P < 0.05, the statistical significance is achieved, and the SPSS19.0 software package is adopted for statistical processing.
Example 3, results of the experiment
3.1 Effect on Lung-to-Dry-to-weight ratio, brain-to-Dry-to-Wet ratio, RV/HW in mice
After the mice are raised in a low-pressure and low-oxygen environment for 3 days, the lung dry-wet ratio and the brain dry-wet ratio of the model group mice are obviously reduced, and the difference is significant (P is less than 0.05). Under the low-pressure and low-oxygen environment, compared with a solvent control group, the dry-wet ratio of the lung of the endothelial progenitor cell group mouse is obviously increased, and the difference has statistical significance (P is less than 0.05). After the mice are raised in a low-pressure and low-oxygen environment for 7 days, the lung dry-wet ratio and the brain dry-wet ratio of the model group mice are obviously reduced, the right heart index is obviously increased, and the difference is significant (P is less than 0.05). Under the low-pressure and low-oxygen environment, compared with a solvent control group, the lung dry-wet ratio of the endothelial progenitor cell group mice is obviously increased, the right heart index is obviously reduced, and the difference has statistical significance (P is less than 0.05). (results are shown in FIG. 1)
3.2 Effect on mouse inflammatory factor indices IL-6, TNF-alpha
After the mice are raised in a low-pressure low-oxygen environment for 3 days and 7 days, IL-6 and TNF-alpha in hearts and brains of model mice are obviously increased, and the difference is significant (P is less than 0.05). Under the low-pressure and low-oxygen environment, the IL-6 and TNF-alpha in the heart and the brain of the mice in the EPCs treatment group are obviously reduced compared with those in the solvent control group, and the difference has statistical significance (P is less than 0.05). (results are shown in FIG. 2)
3.3 Effect on mice RBC, HGB and HCT
After the mice are raised in a low-pressure and low-oxygen environment for 7 days, the BC, HGB and HCT of the model group mice are obviously increased, and the difference is significant (P is less than 0.05). Under the low-pressure and low-oxygen environment, compared with a solvent control group, the mouse RBC, HGB and HCT of the EPCs group are obviously reduced, and the difference has statistical significance (P is less than 0.05). The group differences of the mice raised in the low-pressure and low-oxygen environment for 3 days are not obvious.
(results are shown in FIG. 3)
The results show that the EPCs have a protective effect on cerebral edema, pulmonary edema and the like of a mouse simulating the 5500m acute plateau environment, and can be developed into a product for preventing or treating acute altitude diseases.
The above description is only for the purpose of illustrating the preferred embodiments of the present invention and is not to be construed as limiting the invention, and any modifications, equivalents and the like that are within the spirit and principle of the present invention are included in the present invention.
The foregoing embodiments and methods described herein may vary based on the abilities, experience, and preferences of those skilled in the art.
Claims (10)
1. An application of endothelial progenitor cells in preparing the medicines for preventing or treating acute altitude diseases.
2. The use of the endothelial progenitor cells of claim 1 in the preparation of a medicament for the prevention or treatment of acute altitude sickness, wherein the endothelial progenitor cells are obtained from peripheral blood, bone marrow, and cord blood of an animal; the endothelial progenitor cells contain CD31, CD33, CD133 and VEGF surface antigen; the endothelial progenitor cells are labeled with the dye PKH 26.
3. Use of endothelial progenitor cells according to claim 1 or 2 for the preparation of a medicament for the prevention or treatment of acute altitude sickness, wherein the acute altitude sickness is selected from the group consisting of acute altitude sickness occurring in a high altitude environment.
4. The use of the endothelial progenitor cells of claim 3 for the preparation of a medicament for the prevention or treatment of acute altitude sickness, wherein the acute altitude sickness comprises altitude coma, altitude cerebral edema, altitude pulmonary edema or a mixed type disease with simultaneous symptoms of brain and lung abnormalities.
5. The use of the endothelial progenitor cells of claim 3 for preparing a medicament for preventing or treating acute altitude sickness, wherein the medicament is prepared in the form of injection.
6. The use of the endothelial progenitor cells of claim 3 in the preparation of a medicament for preventing or treating acute altitude sickness, wherein the medicament comprises the endothelial progenitor cells and pharmaceutically acceptable excipients.
7. The use of the endothelial progenitor cells of claim 6, wherein the pharmaceutically acceptable excipients are selected from one or more of pH regulator, surfactant, suspending agent, antioxidant, isotonic regulator, bacteriostatic agent, bulking agent and protein drug protective agent.
8. The use of the endothelial progenitor cells of claim 6 or 7 in the preparation of a medicament for preventing or treating acute altitude sickness, wherein the medicament is formulated as an injection.
9. Use of endothelial progenitor cells according to claim 6 or 7 for the preparation of a medicament for the prevention or treatment of acute altitude sickness, wherein the storage temperature of the medicament is 30-40 ℃, preferably 37 ℃.
10. Use of the endothelial progenitor cells in the preparation of a medicament for preventing or treating acute altitude sickness according to claim 6 or 7, wherein the content of the endothelial progenitor cells in the unit preparation of the medicament is 1 x 105One/ml to 10X 105The content of endothelial progenitor cells per ml, preferably per unit preparation of the medicament, may be 1X 1052X 10 pieces/ml53X 10 pieces/ml54X 10 pieces/ml55X 10 pieces/ml56X 10 pieces/ml57X 10 pieces/ml58 × 10 pieces/ml5Each/ml, 9X 105Each/ml, 10X 105One per ml.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010939222.5A CN111973633A (en) | 2020-09-09 | 2020-09-09 | Application of endothelial progenitor cells in preparation of medicine for preventing or treating acute altitude disease |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010939222.5A CN111973633A (en) | 2020-09-09 | 2020-09-09 | Application of endothelial progenitor cells in preparation of medicine for preventing or treating acute altitude disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111973633A true CN111973633A (en) | 2020-11-24 |
Family
ID=73450978
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010939222.5A Pending CN111973633A (en) | 2020-09-09 | 2020-09-09 | Application of endothelial progenitor cells in preparation of medicine for preventing or treating acute altitude disease |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111973633A (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080206200A1 (en) * | 2007-02-28 | 2008-08-28 | Wary Kishore K | Selected endothelial progenitor cells and methods for use |
| CN106397541A (en) * | 2016-03-25 | 2017-02-15 | 泰山医学院 | Application of high-density protein mimic peptide Reverse-D-4F in preparation of medicines for treating LPS-induced respiratory distress syndrome |
| CN108904536A (en) * | 2018-07-25 | 2018-11-30 | 广州赛莱拉干细胞科技股份有限公司 | Application of the endothelial progenitor cells in the cerebral arterial thrombosis drug of preparation treatment convalescence and/or sequela stage |
| CN111603481A (en) * | 2019-02-25 | 2020-09-01 | 叶宏一 | Methods of treating inflammatory diseases |
-
2020
- 2020-09-09 CN CN202010939222.5A patent/CN111973633A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080206200A1 (en) * | 2007-02-28 | 2008-08-28 | Wary Kishore K | Selected endothelial progenitor cells and methods for use |
| CN106397541A (en) * | 2016-03-25 | 2017-02-15 | 泰山医学院 | Application of high-density protein mimic peptide Reverse-D-4F in preparation of medicines for treating LPS-induced respiratory distress syndrome |
| CN108904536A (en) * | 2018-07-25 | 2018-11-30 | 广州赛莱拉干细胞科技股份有限公司 | Application of the endothelial progenitor cells in the cerebral arterial thrombosis drug of preparation treatment convalescence and/or sequela stage |
| CN111603481A (en) * | 2019-02-25 | 2020-09-01 | 叶宏一 | Methods of treating inflammatory diseases |
Non-Patent Citations (6)
| Title |
|---|
| MARKUS BRUNNER ET AL.: ""Elevated Levels of Circulating Endothelial Progenitor Cells in Head and Neck Cancer Patients"", 《JOURNAL OF SURGICAL ONCOLOGY》 * |
| MARKUS BRUNNER ET AL.: ""Elevated Levels of Circulating Endothelial Progenitor Cells in Head and Neck Cancer Patients"", 《JOURNAL OF SURGICAL ONCOLOGY》, vol. 98, 15 September 2008 (2008-09-15), pages 545 - 550 * |
| 喻安永: ""脾脏截留循环内皮祖细胞及高原环境对大鼠颅脑损伤修复的影响"", 《中国优秀博硕士学位论文全文数据库(博士) 医药卫生科技辑》 * |
| 喻安永: ""脾脏截留循环内皮祖细胞及高原环境对大鼠颅脑损伤修复的影响"", 《中国优秀博硕士学位论文全文数据库(博士) 医药卫生科技辑》, no. 01, 15 January 2016 (2016-01-15), pages 64 - 65 * |
| 崔建华 等: "《高原卫生防病知识手册》", vol. 1, 30 June 2010, 军事医学科学出版社, pages: 60 - 61 * |
| 邓志宽 等: ""血管内皮生长因子在高原脑水肿形成中作用的实验研究"", 《中国临床神经科学》, vol. 13, no. 4, 31 December 2005 (2005-12-31), pages 362 - 364 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6294476B2 (en) | Use of anhydroicaritin in the manufacture of a medicament for preventing or treating cytopenias | |
| CN103385976B (en) | The antitumor application thereof of Pu'er tea or its extract | |
| CN108904533A (en) | Dental pulp mescenchymal stem cell is preparing the purposes in cirrhosis treatment drug | |
| CN105148316A (en) | Sterile zinc-based montmorillonite Band-Aid as well as preparation method and application thereof | |
| CN111759896A (en) | Pharmaceutical application of total triterpene of pawpaw | |
| CN111973633A (en) | Application of endothelial progenitor cells in preparation of medicine for preventing or treating acute altitude disease | |
| CN103690935B (en) | Freeze-drying medicine composition containing thymalfasin | |
| CN104546822B (en) | The medical usage of epimedium aglucone | |
| CN115531473A (en) | Compound essential oil for treating skin diseases and pharmaceutical composition containing same | |
| Li et al. | The effects of maggot secretions on the inflammatory cytokines in serum of traumatic rats | |
| WO2021249402A1 (en) | Effects of cell-free fat liquid extract on macrophage polarization modulation and disease treatment | |
| CN108434166A (en) | A kind of " Xuesaitong Injection " pharmaceutical composition and preparation method thereof, preparation and application | |
| CN101156849A (en) | An alepsin slow-releasing gel for promoting paradontal part reborn as well as preparation method and application | |
| CN1739682A (en) | Nudiflorous beautyberry soft capsule for body cavity and its prepn | |
| CN110215523B (en) | Application of methyl hispolon in preparation of anti-cervical cancer drugs | |
| CN113730447A (en) | Traditional Chinese medicine for promoting wound healing, extract and application | |
| CN114053305A (en) | Application of cell-free fat extract in treating lung diseases | |
| CN105232617A (en) | Application of astragalosides to preparation of medicine for preventing or treating microwave radiation induced nerve cell injury, pharmaceutical composition and food | |
| CN101574498B (en) | Compound cornu cervi pantotrichum bone strengthening capsule for treating osteoporosis and method for quatitatively determining the quality thereof | |
| CN111588763A (en) | Thrombus dredging medicine, preparation method and content determination method | |
| CN105012348A (en) | Bioactive vaginal suppository containing growth factors | |
| CN112891366B (en) | Traditional Chinese medicine active ingredient formula for treating postmenopausal osteoporosis and application thereof | |
| CN104758310B (en) | Compound montmorillonite sucrose ointment and its preparation method and application | |
| CN116270828B (en) | Traditional Chinese medicine composition for wound healing and preparation method thereof | |
| CN102362885B (en) | Traditional Chinese medicine composition for treating puerperal lactation deficiency and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20201124 |
|
| RJ01 | Rejection of invention patent application after publication |